The European Medicines Agency has again declined to recommend approval for Celgene's Revlimid, prompting the company to withdraw its application to market the anemia drug for transfusion-dependent patients with myelodysplastic syndromes. The drugmaker said it will not abandon plans to seek approval for the indication in Europe despite the agency's negative review.

Related Summaries